TMCnet - World's Largest Communications and Technology Community



Research and Markets: PharmaPoint: Ulcerative Colitis - Canada Drug Forecast and Market Analysis to 2022
[May 07, 2014]

Research and Markets: PharmaPoint: Ulcerative Colitis - Canada Drug Forecast and Market Analysis to 2022

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "PharmaPoint: Ulcerative Colitis - Canada Drug Forecast and Market Analysis to 2022" report to their offering.

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

There are three UC-approved biologics in Canada, which are the TNF inhibitors, Remicade, Humira and Simponi. Remcade has the larger potential patient pool, as it was approved for use in UC patients long before Humira (in 2013), which was only approved for UC in 2013. It can also be used either alone or in combination with conventional therapy. This, together with its high annual cost of therapy, means that Remicade experiences strong uptake in the Canadian UC market, which positions it as the market-leading therapy.


  • Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in Canada from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the Canada Ulcerative Colitis market.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

  • Remicade (infliximab)
  • Humira (adalimumab)
  • Simponi (golimumab)
  • Asacol HD (mesalamine)
  • Lialda (mesalamine)
  • Pentasa (mesalamine)
  • Uceris (budesonide)

6 Opportunity and Unmet Need

  • Unmet Needs
  • Unmet Needs Gap Analysis
  • Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools
  • Predictors of Medically-Refractory Disease

7 Pipeline Assessment

  • Entyvio (vedolizumab)
  • Xeljanz (tofacitinib)

8 Market Outlook

9 Appendix

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy